Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

854
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
854
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.4K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Cancer Therapies02:49

Cancer Therapies

9.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.6K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-1α Expands SLC2A1highSPP1highIFNlow Myeloid Cells to Drive Immune Escape and Malignant Transformation of Pre-cancers.

Cancer research·2026
Same author

Myeloid-Derived Suppressor Cells in Inflammatory Arthritis.

International journal of molecular sciences·2026
Same author

Aptamers: Current Applications in Leukemia Diagnostics and Therapeutics.

Nucleic acid therapeutics·2026
Same author

High-Density Lipoprotein Nanoparticles Delivering Liver X Receptor Agonist for the Treatment of Age-Related Macular Degeneration.

Molecular pharmaceutics·2026
Same author

Intermetallic nanoassemblies potentiate systemic STING activation.

Science (New York, N.Y.)·2026
Same author

Mastering particle size analysis: lessons, challenges, and future directions from the FDA-CRCG workshop.

AAPS open·2026

Related Experiment Video

Updated: Dec 9, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.1K

Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs.

Alireza Hassani Najafabadi1,2, Jing Zhang3,4, Marisa E Aikins1,2

  • 1Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.

Nano Letters
|September 14, 2020
PubMed
Summary

This study introduces a novel nanovaccine targeting aldehyde dehydrogenase (ALDH)-high cancer stem cells (CSCs). This approach, combined with immunotherapy, effectively reduced CSCs and improved survival in preclinical cancer models.

Keywords:
Cancer stem cellsaldehyde dehydrogenasebreast cancercancer vaccinemelanoma

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K

Related Experiment Videos

Last Updated: Dec 9, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Cancer stem cells (CSCs) are crucial drivers of tumor metastasis and recurrence.
  • Targeting and eliminating CSCs in vivo remains a significant challenge in cancer therapy.
  • Aldehyde dehydrogenase (ALDH) is a key marker for CSC identification and isolation.

Purpose of the Study:

  • To develop and evaluate a novel vaccination strategy targeting ALDH-high CSCs.
  • To investigate the efficacy of nanodisc-based vaccination against CSCs.
  • To assess the combined therapeutic potential of ALDH vaccination and anti-PD-L1 therapy.

Main Methods:

  • Identification of ALDH1-A1 and ALDH1-A3 epitopes from CSCs.
  • Development of synthetic high-density lipoprotein nanodiscs for ALDH vaccination.
  • Evaluation of nanodisc vaccination in combination with anti-PD-L1 therapy in murine models.

Main Results:

  • Nanodisc vaccination enhanced antigen presentation and induced robust ALDH-specific T cell responses.
  • Combined nanovaccine and anti-PD-L1 therapy demonstrated potent antitumor efficacy.
  • The therapeutic strategy significantly prolonged survival in preclinical cancer models.

Conclusions:

  • This study presents the first nanovaccine strategy targeting CSCs via ALDH.
  • The approach effectively reduces ALDH-high CSCs and enhances antitumor immunity.
  • This novel strategy offers a promising new avenue for cancer immunotherapy.